-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430

Benzinga·10/08/2026 14:41:02
RBC Capital analyst Luca Issi maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $430.